Status:
ACTIVE_NOT_RECRUITING
tDCS as Adjunctive Therapy to Cognitive Stimulation in Medical Students With Depression
Lead Sponsor:
Universidad Nacional Autonoma de Mexico
Conditions:
Clinical Trial
Eligibility:
All Genders
18-30 years
Phase:
NA
Brief Summary
Major depressive disorder (MDD) is a major public health problem, it negatively affects cognition and cognitive deficits affect information processing speed, attention, memory, executive function and ...
Detailed Description
Cognitive training has demonstrated the potential to produce broad benefits in functional cognitive. As a fundamental and essential cognitive skill and essential, working memory supports complex think...
Eligibility Criteria
Inclusion
- Age18 - 30 years old.
- Vaccinated against SARS-COV2 virus.
- Students of the Faculty of Medicine of the UNAM.
- Fluent in Spanish.
- Adequate visual and auditory acuity to be able to perform neuropsychological tests and perform cognitive stimulation.
- Depressive symptoms with working memory impairment (diagnosed by applying a specific neuropsychological battery).
- That they are not under antidepressant pharmacological treatment prior to admission to the research.
- Good general health without medical illnesses (systemic arterial hypertension, diabetes mellitus, dyslipidemias, infections, thyroid disease, vitamin deficiencies) that do not interfere with the study.
- Willingness to participate in a scheduled 8-week study and able to attend scheduled evaluations.
Exclusion
- Any neurological disease that allows suspicion of cognitive failure other than depression, such as Parkinson's disease, multiple infarct dementia, Huntington's disease, hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history of head injury with loss of alertness.
- Participants with history with severe psychiatric disorders according to DSM-5 (bipolar disorder, schizophrenia, chronic depression) or psychotic features, agitation or behavioral problems in the last three months that could lead to difficulties in complying with the protocol.
- History of psychoactive substance abuse and current alcohol use with pattern of abuse or dependence in the past two years.
- Participants with alterations in a conventional electroencephalogram (paroxysmal phenomena identified by a neurophysiologist).
- Participants with pacemakers, intracranial metal objects or history of brain surgery, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.
Key Trial Info
Start Date :
July 22 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 26 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06562387
Start Date
July 22 2024
End Date
August 26 2025
Last Update
August 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universidad Nacional Autónoma de México
Mexico City, Coyoacan, Mexico, 04510